[go: up one dir, main page]

MX2011008763A - Peptidos foxm1 y vacunas que contienen los mismos. - Google Patents

Peptidos foxm1 y vacunas que contienen los mismos.

Info

Publication number
MX2011008763A
MX2011008763A MX2011008763A MX2011008763A MX2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A MX 2011008763 A MX2011008763 A MX 2011008763A
Authority
MX
Mexico
Prior art keywords
peptides
nucleic acids
present
same
cytotoxic
Prior art date
Application number
MX2011008763A
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011008763A publication Critical patent/MX2011008763A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona péptidos aislados que tienen la secuencia de aminoácido de la SEC ID NO: 34 o fragmentos de la misma, que enlazan a antígenos HLA e inducen un linfocito citotóxico T (CTL). La presente invención proporciona además péptidos que incluyen una, dos o varias inserciones, substituciones o adiciones de aminoácidos a los péptidos o fragmentos antes mencionados, aunque aún tienen capacidad de inducción de célula citotóxica T. Se proporcionan además ácidos nucleicos que codifican cualesquiera de los péptidos antes mencionados así como substancias o composiciones farmacéuticas que incluyen cualesquiera de los péptidos o ácidos nucleicos antes mencionados. Los péptidos, ácidos nucleicos, substancias o composiciones farmacéuticas de la presente invención, se pueden utilizar para tratar cáncer o tumor.
MX2011008763A 2009-02-18 2010-02-17 Peptidos foxm1 y vacunas que contienen los mismos. MX2011008763A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15340809P 2009-02-18 2009-02-18
PCT/JP2010/001005 WO2010095428A1 (en) 2009-02-18 2010-02-17 Foxm1 peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
MX2011008763A true MX2011008763A (es) 2011-09-09

Family

ID=42633716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008763A MX2011008763A (es) 2009-02-18 2010-02-17 Peptidos foxm1 y vacunas que contienen los mismos.

Country Status (15)

Country Link
US (1) US8617562B2 (es)
EP (1) EP2408912B1 (es)
JP (1) JP5728717B2 (es)
KR (1) KR101713586B1 (es)
CN (1) CN102405285B (es)
BR (1) BRPI1008887A2 (es)
CA (1) CA2752560C (es)
DK (1) DK2408912T3 (es)
ES (1) ES2618896T3 (es)
IL (1) IL214435A0 (es)
MX (1) MX2011008763A (es)
RU (1) RU2560431C2 (es)
SG (1) SG173751A1 (es)
TW (1) TWI469791B (es)
WO (1) WO2010095428A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032899A1 (en) 2007-08-20 2022-07-27 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
JP6159996B2 (ja) * 2012-03-09 2017-07-12 株式会社富士薬品 ペプチドを含む医薬組成物
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
HK1251924A1 (en) * 2015-10-08 2019-05-03 Oncotherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
CN105524159B (zh) * 2015-11-16 2021-04-09 西南交通大学 具有癌细胞选择性杀伤和迁移抑制作用的多肽分子与用途
CN105999227B (zh) * 2016-08-12 2019-08-06 湖南大学 FOXM1蛋白氮端（1-234 aa）的表达及其用途
EP3522909A4 (en) 2016-10-07 2020-07-08 Board of Regents, The University of Texas System HLA RESTRICTED VGLL1 PEPTIDES AND THEIR USE
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
RS63873B1 (sr) * 2018-04-11 2023-02-28 Enterome S A Antigenski peptidi za prevenciju i lečenje raka
CN109055327B (zh) * 2018-07-23 2021-04-06 浙江工业大学 醛酮还原酶突变体及其应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN114591400B (zh) * 2022-03-29 2022-10-21 西南交通大学 一组靶向FoxM1-DBD多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
EP0846761A1 (en) 1996-12-09 1998-06-10 Introgene B.V. A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
KR100653590B1 (ko) 1998-06-25 2006-12-04 교고 이또 시클로필린 ｂ 유래의 종양 항원 펩티드
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2448881A1 (en) 2001-06-04 2002-12-12 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants ii
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050130899A1 (en) 2001-12-10 2005-06-16 Kyogo Itoh Tumor antigens
US20040109844A1 (en) * 2002-08-28 2004-06-10 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
ES2320443T3 (es) 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1615658A1 (en) 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
EP1747284A4 (en) 2004-02-06 2009-03-11 Wyeth Corp DIAGNOSIS AND THERAPEUTICS AGAINST CANCER
CN1977052B (zh) 2004-03-23 2012-09-05 肿瘤疗法科学股份有限公司 与kif11基因相关的双-链分子及载体
EP1730533A1 (en) 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP2006141208A (ja) 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2298895A1 (en) 2005-07-27 2011-03-23 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
EP1806413A1 (en) 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
US20090311685A1 (en) 2006-04-20 2009-12-17 Oncotherapy Science, Inc NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer
EP4032899A1 (en) 2007-08-20 2022-07-27 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
SG183698A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same
RU2733985C2 (ru) 2009-03-18 2020-10-09 Онкотерапи Сайенс, Инк. Пептиды neil3 и включающие их вакцины

Also Published As

Publication number Publication date
CA2752560C (en) 2017-01-24
JP2012517799A (ja) 2012-08-09
EP2408912A4 (en) 2013-04-17
AU2010216980A1 (en) 2011-08-25
RU2560431C2 (ru) 2015-08-20
EP2408912A1 (en) 2012-01-25
WO2010095428A1 (en) 2010-08-26
SG173751A1 (en) 2011-09-29
RU2011138160A (ru) 2013-03-27
BRPI1008887A2 (pt) 2016-03-01
US20120156231A1 (en) 2012-06-21
TW201032821A (en) 2010-09-16
KR20110117241A (ko) 2011-10-26
ES2618896T3 (es) 2017-06-22
TWI469791B (zh) 2015-01-21
CA2752560A1 (en) 2010-08-26
JP5728717B2 (ja) 2015-06-03
EP2408912B1 (en) 2017-01-18
DK2408912T3 (en) 2017-03-20
US8617562B2 (en) 2013-12-31
CN102405285A (zh) 2012-04-04
CN102405285B (zh) 2015-04-22
IL214435A0 (en) 2011-09-27
KR101713586B1 (ko) 2017-03-08

Similar Documents

Publication Publication Date Title
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TR201908291T4 (tr) Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit.
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EA202091251A2 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
CO7170127A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos
UA97095C2 (ru) Противораковая вакцина, которая содержит опухолевоассоциированный пептид, который связывается с молекулами лейкоцитарного антигена человека (hla) класса i или ii, и ее применение в производстве лекарственного средства
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
MX374682B (es) Moléculas de unión a 4-1bb.
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
EP2528937A4 (en) MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
EA201291004A1 (ru) Пептиды ect2 и включающие их вакцины
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
TH158366A (th) Topk เปปไทด์ และวัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
FG Grant or registration